Table 1 Demographic and clinical features at switch to dual therapy
Variables | From tenofovir/emtricitabine n (%) (n = 364) | From abacavir/lamivudine n (%) (n = 65) | p-valuea |
|---|---|---|---|
Male | 249 (68.4) | 52 (80.0) | 0.060 |
Age, in years, mean (SD) | 48.1 (10.2) | 51.0 (10.4) | Â |
 < 40 | 65 (17.9) | 5 (7.7) | 0.093 |
 40–49 | 145 (39.8) | 26 (40.0) |  |
 ≥ 50 | 154 (42.3) | 34 (52.3) |  |
Intravenous Drug Use | 85 (27.6) | 15 (25.9) | 0.953 |
HCV co-infection | 134 (36.8) | 24 (36.9) | 0.987 |
CD4 cell count, cell/mm3, mean (SD) | 631.6 (295.6) | 678.1 (342.2) | Â |
 < 200 | 15 (4.9) | 1 (1.8) | 0.674 |
 200–349 | 35 (11.4) | 8 (14.6) |  |
 350–499 | 51 (16.7) | 8 (14.6) |  |
 ≥ 500 | 205 (67.0) | 38 (69.1) |  |
Positive HIV-RNA, >  37 copies/mL | 37 (12.3) | 6 (11.3) | 0.835 |
Time (months) in tenofovir/abacavir | 110.0 (68.3) | 110.4 (78.7) | 0.970 |
Dual regimens: | |||
 Atazanavir/r + 3TC (regimen 1) | 121 (33.2) | 17 (26.2) | < 0.001 |
 Darunavir/r + 3TC (regimen 2) | 84 (23.1) | 14 (21.5) |  |
 Lopinavir/r + 3TC (regimen 3) | 31 (8.5) | 1 (1.5) |  |
 Raltegravir/dolutegravir+PI/r (regimen 4) | 128 (35.2) | 33 (50.8) |  |
Number of patients with at least one previous virological failure | 79 (21.7) | 25 (38.5) | 0.004 |